In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Commentary|Videos|May 15, 2024
Strategies to Improve CAR T-cell Durability in Lymphoma
Author(s)Samuel Yamshon, MD
Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.
Advertisement
Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.
Advertisement
Related to this article
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
5